Tirzepatide 10mg
Dual GIP/GLP‑1 receptor agonist studied for metabolic health, insulin sensitivity, and weight‑loss mechanisms.
Research use only. Not for human or veterinary use.
-
Free worldwide shipping on all orders over $100
-
Delivers in: 3-7 Working Days Shipping & Return
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists[3][4].
- Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
- Easy measuring: At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors[1][2]. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation[2]. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials[3][4]. Its ~5‑day half‑life enables convenient once‑weekly administration[1].
Observations from clinical trials and published literature.
- Glycemic control: Significant HbA1c reductions in type 2 diabetes trials[4][9].
- Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses)[3][4].
- Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies[9].
- Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence[1][5].
- Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
About: https://peptidedosages.com/single-peptide-dosages/tirzepatide-10mg-vial-dosage-protocol/
Research Use Only: Not for human or veterinary use.
| Strength | |
|---|---|
| Pack size |
